# Type 1 Diabetes Mellitus FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/type-1-diabetes-mellitus

> 10 upcoming FDA catalysts in type 1 Diabetes Mellitus: technosphere insulin (MNKD) on March 2027 (primary completion); technosphere insulin (MNKD) on Mar to Jun 2027 (topline data readout); frexalimab (SNY) on Apr to Jul 2027 (topline data readout); brivekimig (SNY) on Apr to Jul 2027 (topline data readout); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 20, 2025 | [BMF-219 primary completion](https://sec-api.dev/pdufa/bmf-219) | BMEA | Type 1 Diabetes Mellitus | completed | "NCT06152042 (Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-20 (ACTUAL); Lead Sponsor Biomea Fusion Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06152042)) |
| March 2027 | [Technosphere insulin primary completion](https://sec-api.dev/pdufa/technosphere-insulin) | MNKD | Type 1 Diabetes Mellitus | scheduled | "NCT07224321 (INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Mannkind Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07224321)) |
| Mar to Jun 2027 | [Technosphere insulin topline data readout](https://sec-api.dev/pdufa/technosphere-insulin) | MNKD | Type 1 Diabetes Mellitus | scheduled | "NCT07224321 (INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Mannkind Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07224321)) |
| Apr to Jul 2027 | [Frexalimab topline data readout](https://sec-api.dev/pdufa/frexalimab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06111586 (Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06111586)) |
| Apr to Jul 2027 | [Brivekimig topline data readout](https://sec-api.dev/pdufa/brivekimig) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06812988 (Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812988)) |
| April 2027 | [Frexalimab primary completion](https://sec-api.dev/pdufa/frexalimab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06111586 (Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06111586)) |
| April 2027 | [Brivekimig primary completion](https://sec-api.dev/pdufa/brivekimig) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06812988 (Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812988)) |
| Mar to Jun 2028 | [TZIELD® (teplizumab) topline data readout](https://sec-api.dev/pdufa/teplizumab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06791291 (Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06791291)) |
| March 2028 | [TZIELD® (teplizumab) primary completion](https://sec-api.dev/pdufa/teplizumab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06791291 (Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06791291)) |
| Jun to Sep 2028 | [TZIELD® (teplizumab) topline data readout](https://sec-api.dev/pdufa/teplizumab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT07088068 (A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07088068)) |
| June 2028 | [TZIELD® (teplizumab) primary completion](https://sec-api.dev/pdufa/teplizumab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT07088068 (A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07088068)) |

## Drugs

- [BMF-219](https://sec-api.dev/pdufa/bmf-219) (BMEA)
- [Technosphere insulin](https://sec-api.dev/pdufa/technosphere-insulin) (MNKD)
- [Frexalimab](https://sec-api.dev/pdufa/frexalimab) (SNY)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [TZIELD® (teplizumab)](https://sec-api.dev/pdufa/teplizumab) (SNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/type-1-diabetes-mellitus.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Type 1 Diabetes Mellitus FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/type-1-diabetes-mellitus

```bibtex
@misc{secapidev_indications_type_1_diabetes_mellitus_20261116,
  title        = {Type 1 Diabetes Mellitus FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/type-1-diabetes-mellitus}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_type_1_diabetes_mellitus_20261116","title":"Type 1 Diabetes Mellitus FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/type-1-diabetes-mellitus","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
